Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia

Ezetimibe is a lipid-lowering drug that inhibits the intestinal absorption of dietary and biliary cholesterol by blocking passage across the intestinal wall. The efficacy and safety of adding ezetimibe to ongoing statin therapy in patients with primary hypercholesterolemia was evaluated in a randomi...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of cardiology 2002-11, Vol.90 (10), p.1084-1091
Main Authors: Gagné, Claude, Bays, Harold E, Weiss, Stuart R, Mata, Pedro, Quinto, Katherine, Melino, Michael, Cho, Meehyung, Musliner, Thomas A, Gumbiner, Barry
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Anticholesteremic Agents - administration & dosage
Azetidines - administration & dosage
Biological and medical sciences
Cardiology
Cholesterol
Cholesterol, HDL
Cholesterol, LDL - blood
Double-Blind Method
Drug Administration Schedule
Drug therapy
Drug Therapy, Combination
Ezetimibe
Female
General and cellular metabolism. Vitamins
Humans
Hypercholesterolemia - drug therapy
Hypercholesterolemia - pathology
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Prospective Studies
Quebec
Treatment Outcome
Triglycerides - blood
United States
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ezetimibe is a lipid-lowering drug that inhibits the intestinal absorption of dietary and biliary cholesterol by blocking passage across the intestinal wall. The efficacy and safety of adding ezetimibe to ongoing statin therapy in patients with primary hypercholesterolemia was evaluated in a randomized, double-blind, placebo-controlled study. The study group included 769 adults (aged ≥18 years) with primary hypercholesterolemia who had not achieved National Cholesterol Education Program (NCEP) Adult Treatment Panel II goals with dietary alteration and statin monotherapy. Patients receiving a stable dose of a statin for ≥6 weeks were randomized to receive concurrent treatment with placebo (n = 390) or ezetimibe (n = 379), 10 mg/day, in addition to continuing their open-label statin for 8 weeks. The primary efficacy variable was the percent change in low-density lipoprotein (LDL) cholesterol from baseline with statin monotherapy to end point after intervention (secondary variables: high-density lipoprotein [HDL] cholesterol and triglycerides). Ongoing statin therapy plus ezetimibe led to changes of −25.1% for LDL cholesterol (HDL cholesterol +2.7%; triglycerides −14.0%) compared with LDL cholesterol −3.7% (p
ISSN:0002-9149
1879-1913
DOI:10.1016/S0002-9149(02)02774-1